A RANDOMISED OPEN-LABEL PHASE I/II STUDY ADDING ONCOS-102 TO PEMETREXED/CISPLATIN IN PATIENTS WITH UNRESECTABLE MALIGNANT PLEURAL MESOTHELIOMA-12 MONTH ANALYSIS OF BIOMARKERS AND CLINICAL OUTCOMES-MedSci.cn

A RANDOMISED OPEN-LABEL PHASE I/II STUDY ADDING ONCOS-102 TO PEMETREXED/CISPLATIN IN PATIENTS WITH UNRESECTABLE MALIGNANT PLEURAL MESOTHELIOMA-12 MONTH ANALYSIS OF BIOMARKERS AND CLINICAL OUTCOMES

Jaderberg, M; Cedres, S; Paz-Ares, L; Serres, X; Ricordel, C; Isambert, N; Aix, SP; Levitsky, V; Kuryk, L; Moller, AS; Vetrhus, S

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020; 8 (): A220

科室
- - 订阅+
  - 更多科室
工具
服务